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Steven Shoptaw: We don’t know why, but the use
of nicotine is associated with the use of other sub-
stances, whether you look retrospectively in a clini-
cal trial situation or prospectively in carefully defined
groups. The association is always there and always
very clear. My data show that among methadone-
maintained patients who were trying to quit smok-
ing, they were more likely to use illicit drugs on any
day they smoked.  
Anne Joseph:There is no doubt that quitting smok-
ing has health benefits with respect to lung disease
and many other conditions. Whether it has good, bad,
or no effects on chemical dependency outcomes is
still up in the air, unfortunately. For a long time there
were worries, not founded on any data, that there
would be adverse effects. There have been about a
dozen studies that did not seem to demonstrate such
effects, and a few suggested smoking cessation might
even have a beneficial effect on treatment outcomes.
Lirio Covey: Most of the evidence has been on recov-
ered groups, and it shows that if people quit smoking
after being abstinent from alcohol for a while, quit-
ting smoking does not jeopardize that abstinence. Dr.
Sharp and colleagues, however, are talking about peo-
ple in early recovery. We know very little about how
smoking cessation will affect that group. 
I have some concerns. I see a parallel to the state
of our knowledge with regard to smoking and psy-
chiatric conditions such as major depression. We know
a lot about people with past major depression. But
we don’t know what will happen if people stop smok-
ing when they are still depressed or just recently got
over their depression.
Joseph: We just completed a randomized trial of treat-
ment for nicotine dependence given concurrently
with alcohol treatment, comparing it to nicotine treat-
ment delayed by 6 months. The smoking cessation
outcomes were identical in the two groups, in the
neighborhood of 15 or 16 percent at 12 months.
However, there is sometimes a trend and sometimes  a
statistically significant difference in alcohol treatment
outcomes that favors delayed treatment. This is not the
result we were expecting.
Covey: Anne, can you speculate on the explanation
for your finding?
Joseph: One possibility has to do with pharmaco-
logical interactions between nicotine craving and alco-
hol craving. For example, abstinence from ciga-
rettes may cause nicotine craving, and that might
trigger intense craving for alcohol. Depression is
another possible explanation for these findings. Many
alcohol-dependent patients are depressed. If their
depression is exacerbated by nicotine abstinence or
relative nicotine deprivation, perhaps patients will
use alcohol to self-treat their depression.
Shoptaw: When you work with people who have mul-
tiple substances of dependence, removing one 
doesn’t necessarily affect the others. Or it may. We
don’t know.
Joseph: Our study results have yet to be duplicated.
In addition, in contrast to the ATC scenario described
in this article, the nicotine treatment in our study was
not compulsory. All in all, the question of how con-
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currently treating nicotine dependency will affect
other dependency outcomes is still up in the air.
Covey: I think the authors are to be commended
for taking this approach, even though a lot of their
actions and policies are based on very slim evidence.
I can see it as a potential test.
Joseph:  My guess is that when it all settles out, there
will probably be some situations where it’s not right
to treat nicotine dependency, but in the majority of
situations, it’s probably right. Right now we under-
treat nicotine dependency in the majority of drug and
alcohol treatment populations. It is important to exper-
iment with new approaches, such as those Sharp
describes.
Nicotine-free and discharge policies
Shoptaw:The idea of maintaining a smoke-free facil-
ity and targeting nicotine abstinence is really ground-
breaking in terms of tobacco control and conceptu-
alizing tobacco in relation to other substances of
dependence. Once you get the systems aligned for treat-
ing all substances of abuse, it makes sense to expel some-
one for smoking or having tobacco paraphernalia.
Covey: ‘Groundbreaking’ is a very apt term. I was
quite struck when I read this paper. But Sharp and his
colleagues’ approach makes a lot of sense if you look
at nicotine as part of an integrated treatment approach,
with cessation of tobacco use just one among the other
outcomes. The policies and the practices that are
applied to nicotine should then parallel or duplicate
those that have been applied to alcohol or any other
substance.
Joseph: I will play devil’s advocate: There is a real sense
among chemical dependency clinicians that it would
be absolutely wrong to discharge a patient, possibly
compromising his or her chemical dependency treat-
ment, by forcing the tobacco issue. As harmful as
tobacco is to health, there are differences in how acutely
tobacco and illicit drugs compromise patients’ social
and psychological and legal lives. Tobacco will not kill
the patient in the next week, as the other substances
may do if the patient is in crisis.
On the other hand, there is a desperate need to do
more to address nicotine dependence in this population.
So it is hard to know the right place to draw the line. 
Covey:The authors’ approach has theoretical appeal,
but in practical and humanitarian terms, do we really
want to go there at this time, with the limited infor-
mation we have about the impact of smoking cessa-
tion on people in early treatment? 
Shoptaw:  A question—and one I ask about my
own work, too—is this: The authors get a 12-percent
quit rate at 3 months. If you end up with, say, a 5-
percent quit rate at 1 year, is that worth putting every-
body through so much pain?  It’s a low rate.
Joseph: You raise a controversial issue: Are alcohol-
dependent patients’ smoking cessation outcomes really
worse than other individuals’? We have always pre-
sumed they are, but outcomes in the general popula-
tion are proportional to the intensity of treatment.
For a behavioral intervention in a general practice
clinic, 15 percent long-term cessation is pretty good.
We don’t question it. We know that over time, as
people age, more and more quit. They require repeated
attempts. So I am not discouraged by the numbers in
this article.
Shoptaw: We have had methadone-maintained patients
use our behavioral therapy and nicotine replacement
to get smoke-free and feel very proud of having done
so. Then they go home, where they’ve spent 20 years
with their spouse sitting together, watching TV and
smoking. I think that sort of scenario helps to explain
the relatively poor smoke-free outcomes Sharp and
colleagues get at 3 months. A treatment goal that
would be consistent with their approach would be to
begin providing smoking cessation for the family,
so you send your people home to situations that reflect
what you practiced in the treatment environment.
My hat is off to the ATCs because they took the
risk to go down this road and they are documenting
their outcomes. The results may turn out to be dis-
appointing, but I think it’s great that they’ve taken
this path.
Joseph: There is a distinction between an institutional
no-smoking policy and the intervention practice pol-
icy with respect to smoking. They are two very dif-
ferent things. I think it is quite feasible to introduce
a smoke-free policy into chemical dependency pro-
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policy is an initial step that can and should be taken
because it sets the stage for providing intervention.
Interventions, costs, and generalizability
Shoptaw: Sharp’s approach to nicotine replacement
therapy is a commonsense one.
Joseph: The approach of using higher dose nicotine
replacement therapy based on the baseline amount of
smoking is not strongly grounded in evidence, though
many clinicians follow that practice. The guideline
from AHRQ [the Federal Agency for Healthcare
Research and Quality] does not support adjusting
patch dose on the basis of smoking levels, but it rec-
ommends that if patients feel cravings they can have
additional doses of nicotine or supplements with gum.
That sort of symptomatic treatment makes sense.
Covey: I liked the way the authors created a conducive
environment for their smoking intervention. They
laid the groundwork for over a year or more and really
prepared the staff and treatment community. They
also did marketing and advertising, information and
education.
Shoptaw: I appreciate the way the authors monitor
the bottom line. Initially their referrals dipped and
their cash stream fell. But then the referrals came back,
and that strikes me as very interesting. I’m not sure
what to make of it, or whether it would generalize
to other places.
Joseph:There has been an argument raised for requir-
ing that inpatient chemical dependency facilities be
smoke-free to receive accreditation. That would elim-
inate some of the business disadvantage that smoke-
free facilities now may face. Still, it is hard to imag-
ine we are anywhere near mandating nicotine treatment
to the extent that these authors describe.
Shoptaw: The cost of their nicotine treatment was
$55 per patient. That’s pennies, not a major issue, not
an issue at all. For the value of what you get back, it’s
great. Yet it is still hard to get major payers to cover
NRT and other smoking cessation treatments. That’s
because the gains for implementing a smoke-free pol-
icy are further down the line and aren’t going to be
recovered by the person who is paying for the treat-
ment episode.
Covey: With respect to the authors’ recommenda-
tion for research to determine the long-term impact
of tobacco treatment and recovery, multiple outcomes
will have to be looked at. Not just tobacco cessation,
but also abstinence from other dependencies and other
mental health parameters. Do the patients become
depressed? Do they start developing panic disorders,
hallucinations?
Shoptaw: I wonder how generalizable these authors’
experiences might be. It’s one thing to do what they’ve
done as a publicly funded health care provider, but
it’s not clear whether it will translate into managed
care or HMO situations where executives make the
decisions. Also, the article describes how Sharp’s group
got their staffs to buy in to treating tobacco depen-
dence like every other addictive disease. They laid the
argument out very nicely. But what do you do with
staff members who are highly trained and good at
what they do, yet continue to smoke? I think this
group just told people, ‘If you don’t want to quit smok-
ing, you can go work someplace else.’ In some other
agencies that might not be an acceptable response.
Joseph: The issue of generalizability is very impor-
tant. Can a smoke-free policy and mandatory inter-
vention be accomplished in the absence of a strong
antismoking advocate such as you’re likely to see in a
research project? Can mandatory treatment work for
chemical dependency patients who have more serv-
ice options than the patients in Sharp’s public clinics
do?
I wonder if this would be a suitable question for
NIDA’s Clinical Trials Network, where you actually
could randomize programs to varying degrees of oblig-
atory nicotine dependence treatment, then look at
enrollment, treatment completion rates, drug treat-
ment outcomes, and so forth. Ultimately, the way to
really test these questions is to randomize programs.
That is probably the most difficult kind of research
to do well—but that really is how this question is
going to be figured out. &
A treatment
goal that
would be
consistent
would be to
begin provid-
ing smoking
cessation for
the family.